Check out this interesting min-bio of Ariel Watriss, the latest in IRMA’s “Meet a Friendly Rectal Microbicide Advocate” series on the IRMA website here.  Ariel is one of six new bios just posted a few days ago, including individuals from Kenya, Thailand, the UK, India and Argentina.  Each will be featured on the blog, and you can Read More >>

REGISTER FOR THIS CALL! Raise your hand if you’ve ever felt uncomfortable talking about anal sex and anal health. Have you noticed that people sometimes tend to cringe from embarrassment when the word “rectal” is uttered? Or that they may laugh a little too much, or try to change the subject too quickly? If you can identify Read More >>

via The Boston Globe, by Sean Cahill Initial results from clinical prevention trials of pre-exposure chemoprophylaxis (PrEP), in oral pill form indicate that PrEP could be the “game changer” needed to more effectively fight HIV. PrEP involves taking antiretroviral medications to prevent HIV. PrEP has shown partial efficacy with men who have sex with men (MSM) and Read More >>

viaFenway Health Pre-exposure chemoprophylaxis (PrEP)—taking antiretroviral medications to prevent HIV transmission—could be a “game changer” for HIV prevention. PrEP has demonstrated partial efficacy with men who have sex with men (MSM), transgender women, and heterosexuals in several recent studies. Recent modeling of PrEP implementation coupled with scaled up treatment predicts that PrEP could significantly reduce HIV incidence Read More >>

Via unaids.org Thirty years into the AIDS epidemic, investments in the AIDS response are yielding results, according to a new report released today by United Nations Secretary-General Ban Ki-moon. Titled Uniting for universal access: towards zero new HIV infections, zero discrimination and zero AIDS-related deaths, the report highlights that the global rate of new HIV infections is Read More >>

by Julie Davids, AIDS Foundation of Chicago, HIV Prevention Justice Alliance and IRMA member As noted in these pages and press reports worldwide, the iPrex trial found that daily use of truvada protected gay men, other MSM and trangender women from HIV infection. Updated data presented at this week’s Conference on Retroviruses and Opportunistic Infections (CROI) showed Read More >>